Title:
FXR RECEPTOR AGONIST
Document Type and Number:
WIPO Patent Application WO/2020/001304
Kind Code:
A1
Abstract:
The present invention falls within the field of medical technology, and in particular relates to a compound as shown in formula (I), and a pharmaceutically acceptable salt, ester or stereoisomer thereof, wherein R1, R2, X1, X2, X3, M, Ar, and rings B and L are as defined in the description. Also involved are the preparation methods and pharmaceutical preparations of the compounds, and the uses of same in the preparation of drugs for treating and/or preventing related diseases mediated by FXR receptors, such as alcoholic fatty liver, nonalcoholic fatty liver, primary biliary cirrhosis, lipid metabolism disorders, diabetic complications, and malignant tumors.
More Like This:
| JP2007522225 | Pyridadinone as an A4 integrin antagonist |
| JP2002530387 | INDUSTRIAL APPLICABILITY: Quinoline and quinoxaline compounds |
| WO/2023/114365 | METHODS AND COMPOSITIONS FOR TARGETING PD-L1 |
Inventors:
FANG WENKUI KEN (CN)
WANG TINGZHONG (CN)
CHENG JING (CN)
WANG TINGZHONG (CN)
CHENG JING (CN)
Application Number:
PCT/CN2019/091482
Publication Date:
January 02, 2020
Filing Date:
June 17, 2019
Export Citation:
Assignee:
XUANZHU HAINAN BIOPHARMACEUTICAL CO LTD (CN)
International Classes:
C07D453/06; A61K31/439; A61P1/04; A61P1/16; A61P3/10; A61P7/02; A61P9/10; A61P35/00
Foreign References:
| CN103443099A | 2013-12-11 | |||
| CN107106555A | 2017-08-29 |
Download PDF: